Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DH2S8X
|
|||
| Drug Name |
GT103
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 1 | [1] | |
| Company |
Grid Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Complement factor H (CFH) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Staphylococcus aureus infection | ||||
| NetPath Pathway | IL1 Signaling Pathway | |||
| Reactome | Regulation of Complement cascade | |||
| WikiPathways | Complement and Coagulation Cascades | |||
| Human Complement System | ||||
| Complement cascade | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04314089) Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Grid Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.